Deals In Depth: April 2016
Allergan rebounded from the derailed Pfizer acquisition by signing a $3 billion partnership with Heptares to develop small-molecule muscarinic receptor agonists in CNS diseases; there was a huge consolidation in cardiovascular devices through Abbott's $25 billion purchase of St. Jude Medical. Biopharma funding totaled $1.1 billion, while device fundraising reached $248 million.
You may also be interested in...
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.